Commonly, the therapeutic strategy of blocking the estrogen receptor signaling pathway is effective in estrogen receptor positive breast cancer patients but will lose its effectiveness due to drug resistance during endocrine therapy. This evidence concerns the gene ESR1 and breast cancer.